7/9
06:02 am
veru
Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty [Yahoo! Finance]
Medium
Report
Foresee Pharmaceuticals Appoints Brian J. Groch as Chief Commercial Officer to Spearhead Commercial Launch of FP-001 42 mg for Central Precocious Puberty [Yahoo! Finance]
7/7
06:06 pm
veru
Veru (VERU) was upgraded by
Weiss Ratings from "sell (e+)" to "sell (d-)".
Medium
Report
Veru (VERU) was upgraded by
Weiss Ratings from "sell (e+)" to "sell (d-)".
7/7
09:01 am
veru
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day [Yahoo! Finance]
Low
Report
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day [Yahoo! Finance]
7/7
08:30 am
veru
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
Low
Report
Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
6/5
08:28 am
veru
Veru And 2 Other Intriguing Penny Stocks To Watch [Yahoo! Finance]
High
Report
Veru And 2 Other Intriguing Penny Stocks To Watch [Yahoo! Finance]
6/4
12:47 pm
veru
Veru (VERU) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
High
Report
Veru (VERU) had its "buy" rating reaffirmed by Canaccord Genuity Group Inc.. They now have a $25.00 price target on the stock.
6/1
12:27 am
veru
Earnings call transcript: Veru Inc Q2 2026 shows improved financials [Yahoo! Finance]
Low
Report
Earnings call transcript: Veru Inc Q2 2026 shows improved financials [Yahoo! Finance]
5/15
09:49 am
veru
Veru (VERU) had its price target lowered by Oppenheimer Holdings, Inc. from $25.00 to $24.00. They now have an "outperform" rating on the stock.
Low
Report
Veru (VERU) had its price target lowered by Oppenheimer Holdings, Inc. from $25.00 to $24.00. They now have an "outperform" rating on the stock.
5/13
11:51 am
veru
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript [Seeking Alpha]
Low
Report
Veru Inc. (VERU) Q2 2026 Earnings Call Prepared Remarks Transcript [Seeking Alpha]
5/13
08:57 am
veru
Transcript: Veru Q2 2026 Earnings Conference Call [Yahoo! Finance]
Medium
Report
Transcript: Veru Q2 2026 Earnings Conference Call [Yahoo! Finance]
5/13
06:30 am
veru
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
Low
Report
Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress
5/6
08:30 am
veru
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
Neutral
Report
Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th
4/22
06:08 am
veru
Veru (VERU) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.
Low
Report
Veru (VERU) had its "sell (e+)" rating reaffirmed by
Weiss Ratings.